Neurocrine Nabs $20M
Luke Timmerman3/5/10
Neurocrine Biosciences, the San Diego biotech company developing treatments for neurological and endocrine disorders, said today it has raised gross proceeds of about $20 million in a stock offering. The company (NASDAQ: NBIX) sold 9.1 million shares at $2.20 apiece. Jefferies & Co., the sole book-running manager of the offering, has a 30-day option to buy about 1.36 million more shares.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
